Key result
Higher plasma adenosine is associated with LV dysfunction and remodeling in chronic heart failure.
Why the study?
Despite effective therapies, the prognosis of chronic heart failure remains poor, necessitating new treatment options such as adenosine elevation.
Hypothesis-generating for adenosine as a biomarker in chronic HF; prospective validation required before clinical consideration.
Adenosine as a New Treatment Strategy for CHF CHF results in and from the release of many neurohumoral factors, including catecholamines, renin-angiotensin and cytokines.Despite effective therapies such as angiotensin-converting enzyme inhibitors, β-blockers, aldosterone antagonists and devices, the prognosis of CHF is worse than for most cancers.Because of its high morbidity and mortality, we need new options for the treatment of CHF.Adenosine is reported to attenuate the sympathetic nervous system, renin-angiotensin system, and cytokine system; therefore, elevation of adenosine levels may largely
No takes yet. Share an insight, caveat, or question.
Asanuma et al. (2018) conducted an editorial in Chronic Heart Failure. Plasma adenosine concentration was evaluated on Association with LV ejection fraction (LVEF) <47% vs ≥47% (p=0.027).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: